Navidea Biopharmaceuticals, Inc. Announces Distribution of Series K Preferred Stock to Holders of its Common Stock Jun 16, 2023
Navidea Biopharmaceuticals, Inc. Receives $7.5 Million Cash from Cardinal Health in Lieu of Contingent Milestone Payment Jun 16, 2023
Navidea Biopharmaceuticals, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update Jun 7, 2023
Navidea Biopharmaceuticals, Inc. Welcomes Jill Bieker Stefanelli, Ph.D. to Board of Directors; Alexander L. Cappello Steps Down Jun 1, 2023
Navidea Biopharmaceuticals, Inc. Investors Purchase $1.1 Million in Preferred Shares at Market May 22, 2023
Navidea Biopharmaceuticals, Inc. Promotes Michael Sherman Blue, M.D., FACEP, to Chief Medical Officer May 11, 2023
Navidea Biopharmaceuticals, Inc. Drives Strategy Forward, Shifts Approach for Communications May 8, 2023
Navidea Biopharmaceuticals, Inc. Announces Intent to sell Cardinal Milestone Payment for $8 Million; Secures New $2.75 Million Equity Line of Credit Apr 27, 2023
